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Background: Compared to existing literature on childhood attention deficit hyperactivity disorder (ADHD), little
published adult data are available, particularly outside of the United States. Using General Practitioner (GP)
questionnaires from the United Kingdom, this study aimed to examine a number of issues related to ADHD in
adults, across three cohorts of patients, adults who received ADHD drug treatment in childhood/adolescence but
stopped prior to adulthood; adults who received ADHD drug treatment in childhood/adolescence and continued
treatment into adulthood and adults who started ADHD drug treatment in adulthood.
Methods: Patients with a diagnosis of ADHD and prescribed methylphenidate, dexamfetamine or atomoxetine
were identified using data from The Health Improvement Network (THIN). Dates when these drugs started and
stopped were used to classify patients into the three cohorts. From each cohort, 50 patients were randomly
selected and questionnaires were sent via THIN to their GPs.
GPs returned completed questionnaires to THIN who forwarded anonymised copies to the researchers. Datasets
were analysed using descriptive statistics.
Results: Overall response rate was 89% (133/150). GPs stated that in 19 cases, the patient did not meet the criteria
of that group; the number of valid questionnaires returned was 114 (76%). The following broad trends were
observed: 1) GPs were not aware of the reason for treatment cessation in 43% of cases, 2) patient choice was the
most common reason for discontinuation (56%), 3) 7% of patients who stopped pharmacological treatment
subsequently reported experiencing ADHD symptoms, 4) 58% of patients who started pharmacological treatment
for ADHD in adulthood received pharmacological treatment for other mental health conditions prior to the ADHD
being diagnosed.
Conclusion: This study presents some key findings relating to ADHD; GPs were often not aware of the reason for
patients stopping ADHD treatment in childhood or adolescence. Patient choice was identified as the most
common reason for treatment cessation. For patients who started pharmacological treatment in adulthood, many
patients received pharmacological treatment for comorbidities before a diagnosis of ADHD was made.
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Attention deficit hyperactivity disorder (ADHD) is a
neurodevelopmental disorder, which in the past was con-
sidered to be a condition restricted to childhood [1-3].
ADHD is now recognised as a valid diagnosis in adults as
symptoms and impairments of ADHD are known to per-
sist past childhood and adolescence [1,3-6]. ADHD con-
tinues to be diagnosed mainly in childhood, and for some
patients, the condition will follow a remitting course as
they get older and these patients may no longer expe-
rience the symptoms and impairments of ADHD in adult-
hood. For many whom no longer report symptoms, the
decision to stop treatment is often taken by the adoles-
cents themselves [7]. For others with ADHD diagnosed in
childhood or adolescence, the symptoms and impairments
persist into adulthood and they continue to seek medical
treatment, which may include pharmacological treatment
[7]. Some adults with ADHD are recognised, for the first
time, to have ADHD-associated impairment in adulthood.
In this situation, the diagnosis is based on the persistence
of symptoms and impairments from childhood/adoles-
cence into adult life [5].
Compared to younger patients, adults with ADHD are
more likely to exhibit inattentive symptoms as hyper-
active symptoms tend to diminish throughout the course
of the condition [8]. However, they still suffer from
symptoms such as the inability to sustain attention, dis-
organisation, forgetfulness and poor time manage-
ment skills. In addition, a subset of adults with ADHD
continue to have difficulties with overactive and impul-
sive symptoms; emotional dysregulation is increasingly
being recognised as a related symptom that often co-
occurs with untreated ADHD in adults [9]. There is now
consensus amongst experts that ADHD, which is mainly
diagnosed using the broader Diagnostic and Statistical
Manual of Mental Disorders 4th Edition (DSM-IV) cri-
teria, may currently affect at least 1-2% of adults in the
United Kingdom (UK) and 2-4% worldwide [5,10-13].
The prevalence of ADHD in school-aged children and ado-
lescents in the UK using DSM-IV criteria is estimated at 5%
[14]. The prevalence of hyperkinetic disorder (HKD) in
school-aged children and adolescents in the UK, defined by
the more narrow International Classification of Disease
10th Revision (ICD-10) criteria is estimated at 1.5% [15].
While more evidence is being generated on the nature
of ADHD in adulthood, ADHD guidelines published by
the National Institute for Health and Clinical Excellence
(NICE) in 2008 [3] state that ‘little empirical evidence is
available to guide clinicians on questions such as the
optimum duration of treatment, when it is appropriate
to consider drug discontinuation and how and when to
combine pharmacological and psychological treatments’.
In addition, there are few data in the literature about the
pharmacological management of ADHD in adults,particularly in the context of comorbid symptoms and
syndromes, and particularly in Europe.
Through the use of a survey completed by general
practitioners (GPs) about their patients, this study aimed
to examine a number of issues concerning the diagnosis
and treatment of ADHD in adults within the UK. For
adults who received pharmacological treatment in child-
hood for ADHD and stopped this treatment before rea-
ching adulthood, we sought to examine the reasons for
stopping pharmacological treatment and to determine
whether these patients experienced ADHD symptoms
following cessation of treatment. Also whether they
sought psychological interventions for ADHD and/or
received pharmacological treatments for other men-
tal health conditions following cessation of ADHD drug
treatment.
For the group of patients who started treatment in
childhood and continued to receive pharmacological treat-
ment as an adult, our aim was to determine; whether these
patients also received psychological treatment for ADHD,
whether other mental health conditions were currently
present or had ever been present and were treated as well
as determining whether there was shared care between
GP and specialist services. In the UK, shared care proto-
cols outline ways in which the responsibilities for man-
aging the prescribing of a medicine can be shared between
the specialist and a primary care prescriber (GP) [14].
Shared care aims to facilitate seamless transition between
primary and secondary care.
For those patients who started treatment for ADHD in
adulthood, our aim was to examine whether they had,
and were treated, for other mental health conditions
both prior to and after the ADHD diagnosis was made,
and also whether there were shared care arrangements
between GPs and specialist services.
Methods
Data source
Data from The Health Improvement Network (THIN)
database were used to identify patients that met the cri-
teria for the study (described below). THIN contains
anonymised computerised medical records entered by
GPs in the UK for patient healthcare management. With
coverage of approximately 5.7% of the UK population
(2009), practices included in the database are broadly rep-
resentative of practices in the UK in respect of patients’
demographics and characteristics [16]. GPs participating
in THIN are trained to record medical records using
the Vision general practice system (In Practice Systems;
London, UK) and the validity of data on the database for
research has been supported by a number of studies
[17-20]. Those GPs who contribute to THIN and consent
to provide further information on patients were included
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each questionnaire completed and returned.
Patient identification & selection
The method of patient selection has been described in de-
tail elsewhere [21], in summary; patients who had a
diagnosis of ADHD/HKD and a prescription record for
methylphenidate, dexamfetamine or atomoxetine (ap-
proved drugs for the treatment of ADHD in the UK)
coded on the THIN database during the study period 1st
January 2003 to 31st December 2008 were identified. This
sampling timeframe provided the most recent data avail-
able at the time the study was initiated (2009). The entire
prescription records of the patients, which could include
prescriptions for a study drug issued before 1st January
2003, were examined to determine at what age they
received their first prescription for a study drug, whether
they continued to receive prescriptions or had stopped,
and if they had stopped, at what age they stopped treat-
ment. As the purpose of the study was to examine issues
relating to ADHD treatment in adulthood, of those
patients identified above, only those who had reached the
age of 18 years or greater during the study period were
included. The age of patients was calculated as follows:
once patients reach the age of 15 years, the date of birth
is switched by THIN to the year of birth only (for patients
younger than 15 years, the month of birth is also re-
corded). Therefore, as all patients included in the current
study were aged 18 years or greater, the date of birth was
imputed as 1st January and Year of Birth. Approximate
ages of the patients were calculated at the mid-point of
2010 when questionnaire data were collected.
Identified patients (aged ≥ 18 years during the study
period) were categorised into one of three cohorts:
 Adults who received pharmacological treatment for
ADHD in childhood or adolescence but stopped
before adulthood (Group 1)
 Adults who started pharmacological treatment for
ADHD in childhood or adolescence and continued
treatment into adulthood (Group 2)
 Adults who newly started pharmacological
treatment for ADHD in adulthood (Group 3)
Patients in Group 1 consisted of adult patients who
started ADHD treatment in childhood or adolescence
(6–17 years) and stopped treatment before the age of 18 -
years. A total of 190 patients were identified. From this
cohort, a random sample of 50 patients was selected.
Patients in Group 2 consisted of patients who started
treatment in childhood or adolescence and were still re-
ceiving prescriptions at age ≥ 18 years. A total of 106
patients were identified. From this cohort, a random sam-
ple of 50 patients was identified.Adult patients who started treatment at age 18 years
or older were identified (n = 66 patients). Fifty patients
were randomly selected to form Group 3.
A schematic of patient identification and selection is
provided in Figure 1.
Questionnaire design and distribution
The questionnaires were designed by the researchers
(pharmacist (ICKW), pharmacoepidemiologist (MLM)
and adult psychiatrist (PA)) to address the outcome
measures below. Questionnaires were in a check box
format, although respondents (GPs) had the opportunity
to give additional information, using free text. For most
questions, respondents could provide more than one an-
swer. The questionnaires for the three cohorts were
similar in terms of content and format e.g. patient
demographics, however the context for some of the
topic areas were specific to the patient cohort e.g. for
patients who stopped ADHD treatment before adult-
hood (Group 1), questions regarding psychological ther-
apy for ADHD refer to the period since stopping
medication, whereas for patients in Group 2, those who
continued treatment from childhood into adulthood,
questions refer to patients receiving psychological ther-
apy in addition to pharmacological therapy. GPs were
provided with information on the symptoms of ADHD
(as per NICE guidelines 2008) and information on psy-
chotropic medications (as per British National Formu-
lary). Copies of the questionnaires are available from the
authors on request.
Researchers did not contact the GP practices directly.
Three lists (50 cases for each group) with encrypted pa-
tient and practice ID codes were sent by the researchers
to THIN who deciphered the practice codes and linked
the selected, anonymised patient ID codes to their GP.
THIN has no information which could identify a pa-
tient. THIN printed the questionnaires (with practice
code and patient ID code) and sent them directly to
the GP. The patient ID code enabled the GP to identify
the individual patient(s). Each GP was requested to
complete the questionnaire for their selected patient(s)
and to send back all questionnaires to THIN. THIN
ensured that any personal information (e.g. practice or
hospital identities, anything which could reveal a
doctor’s or patient’s location or personal information)
was removed before forwarding a copy of the question-
naire to the researcher. Questionnaires forwarded to
researchers only contained the encrypted patient ID (as
originally sent to THIN) to link back to the original case
selected; THIN retained the original questionnaires. The
questionnaires were sent to a total of 90 GPs ac
ross the UK (71 – England; four – Northern Ireland; 11 –
Scotland; four – Wales).
3,626 with an ADHD diagnosis, prescription for study drug 
on the database between 2003 and 2008 and 1 treatment 
episode 
3,274 started between 6 
– 12 years 
352 started <6 years or 
> 18 years 
610 had data on 
database into adulthood 
122 
started 
pharmacological 
treatment on database 
> 18 years 
358 stopped 
pharmacological 
treatment on 
database before 18 
years  
252 
continued receiving 
pharmacological 
treatment on 
database > 18 years 
190 registered with 
consenting practice 
(Group 1)  
 
106 registered with 
consenting practice 
(Group 2)   
 
 
66 registered with 
consenting practice 
(Group 3)  
THIN Database 
Figure 1 Flow chart to identify study participants.
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Group 1: Adult patients who started pharmacological
treatment for ADHD in childhood or adolescence but
stopped treatment before adulthood. The reasons for stopping medication.
 The percentage of adult patients who, since stopping
ADHD medications, continued to report ADHD
symptoms.
 The percentage of patients continuing to report
ADHD symptoms, who then received psychological
interventions for ADHD.
 The percentage of adult patients who, since stopping
ADHD medications, receive/received
pharmacological treatments for other mental health
conditions.
 Whether GPs considered ADHD to be the primary
mental health diagnosis.Group 2: Adult patients who started pharmacological
treatment for ADHD in childhood or adolescence and
continued treatment into adulthood. The percentage of adult patients who receive/
received psychological interventions for ADHD.
 The percentage of adult patients who receive/
received pharmacological treatments for
comorbidities and the identification of treated
comorbidities.
 The extent to which shared care protocols exist
between primary and secondary care.
 Whether GPs considered ADHD to be the primary
mental health diagnosis.Group 3: Adult patients who newly started pharmaco-
logical treatment for ADHD in adulthood
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for other mental health conditions before the
diagnosis of ADHD was made.
 Identification of these mental health conditions and
their treatment.
 The percentage of patients who receive/received
treatment (pharmacological/psychological) for
mental health conditions in addition to ADHD
treatment.
 The extent to which shared care protocols exist
between primary and secondary care.
 Whether GPs considered ADHD to be the primary
mental health diagnosis.Questionnaire analysis
Data from completed GP questionnaires were collated
and entered into two Microsoft AccessW databases (first
and second entry). The datasets were compared for data
cleaning purposes and checked for internal consistency;
any differences identified were checked against the source
questionnaire. Only those questionnaires in which the GP
confirmed that the patient met the group criteria (e.g.
a patient in Group 1 had stopped ADHD pharmaco-
logical treatment prior to adulthood) were considered
valid questionnaires for the study and were included in
the analyses.ble 1 Questionnaire response and patient demographics
Group
before
uestionnaire Response
mber of Questionnaires Sent 50
mber of Questionnaires Returned 47
Response Rate 94 (47/5
mber of Returned Questionnaires in which GP confirmed that
tients met criteria of the cohort (Valid Questionnaires)
44
mber of GPs sent questionnaires 40
mber of GPs who returned questionnaires 38
tient Demographics (n = 44)
nder (male,%) 39 (88.6
ean Age (years) at Diagnosis for Males (SD) 9.4 (±3.
ean Age (years) at Diagnosis for Females (SD) 12.0 (±1
ean Age (years) at time of data collection for Males (SD) 20.0 (±1
ean Age (years) at time of data collection for Females (SD) 20.5 (±1
agnosis made by
ychiatrist (N) 30
ediatrician (N) 11
known by GP (N) 3
ther (N) 0
o SD provided as data based on one patient.Descriptive analyses were performed on all valid ques-
tionnaires using Stata/SE version 11.0 (Stata Corp, College
Station, Texas, United States). For each question in the
questionnaires, the responses were analysed in respect of
the total number of questionnaires returned for that group
and in respect of the number of questionnaires where the
data for that question were completed by the GP.Ethical approval
Ethical approval for this study was granted by the
Cambridgeshire 4 Research Ethics Committee (ref: 09/
H0305/81).Results
Questionnaire response
Of the 150 questionnaires (50 per group) that were sent
to 90 GPs, 133 (88.7%) were returned by 80 GPs (64 –
England; three – Northern Ireland; nine – Scotland; four –
Wales) by datalock; of these 115 (86.5%) were for male
patients and 18 (13.5%) for female patients (Table 1).
Of these, 114 valid questionnaires were analysed for this
study (44 in Group 1, 37 in Group 2 and 33 in Group 3)
relating to 100 males (39 in Group 1, 36 in Group 2 and
25 in Group 3). The demographics of the patients are
presented in Table 1.1 – stopped tx
adulthood
Group 2 – continued tx from
childhood into adulthood
Group 3 – started
tx in adulthood
50 50
41 45
0) 82 (41/50) 90 (45/50)
37 33
38 43
31 39
(n = 37) (n = 33)
) 36 (97.3) 25 (75.8)
0) 10.4 (±3.4) 28.7 (±9.6) 10.4
.4) 9* 31.0 (±5.7)
.3) 20.6 (±1.2) 36.7 (±10.4)
.1) 19.4* 38.9 (±11.2)
25 27
7 0
5 3
0 3
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for ADHD in childhood/adolescence and stopped before
adulthood (n = 44)
i) Reasons for Stopping MedicationThe reasons for stopping treatment were not known by
GPs for 19 patients. Analyses were performed based on
the 25 patients in whom the reason was reported by the
GP. The main reasons cited for treatment cessation were
patient choice (n = 14) and improvement in symptoms
(n = 8). The reasons provided by GPs on why the patients
stopped treatment are presented in Table 2.Ta
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thii) Percentage of patients who, since stopping ADHD
medications, continued to report ADHD symptomsTwo GPs answered ‘Unknown’ to this question and so
analyses were performed on 42 patients. Three of the 42
patients (7.1%) experienced ADHD symptoms subsequent
to stopping ADHD medications and for all three patients,
their symptoms were reported to be of moderate severity.
According to the GPs, the majority of patients (92.9%; 39/
42) who stopped pharmacological treatment before adult-
hood did not report experiencing ADHD symptoms
subsequently.iii) Percentage of patients continuing to report ADHD
symptoms, who then received psychological
interventions for ADHDble 2 Reasons for stopping pharmacological treatment for
DHD before adulthood in patients from Group 1 (n = 44)
asons for stopping medication* Frequency % Definite
answer¥
(n = 44) [95% CIs]
(n = 25)
tient did not want to continue
edication (inc. stopping when finished
ams)
14 56.0
[34.9–75.6]
tient had improvements in symptoms 8 32.0
[14.9–53.5]
tient experienced side-effects of
edication
2 8.0
[1.0–26.0]
ther – parental decision of ineffectiveness 1 4.0
[0.1–20.4]
known by GP 15 N/A
known by GP – patient lost to follow-up 4 N/A
espondents could choose more than answer ¥ GPs provided a reason other
an ‘Unknown’.Of the three patients who continued to report ADHD
symptoms, one patient received psychological treatment.
iv) Percentage of patients who, since stopping ADHD
medications, receive/received pharmacological
treatments for other mental health conditions
Two GPs answered ‘Unknown’ to this question and so
analyses were performed on 42 patients. Seven of the 42
patients (16.7%) received medication for other mental
health conditions. Six of these patients were treated for
mood disorder, one of whom was also treated for anger
management. The seventh patient was treated for anxiety.
All seven patients were treated with antidepressants. The
majority of patients (83.3%; 35/42) did not receive
pharmacological treatments for other mental health
conditions, after stopping their ADHD medication.
v) ADHD as the primary mental health diagnosis
GPs were asked if they considered ADHD to be the
primary mental health diagnosis for the patient. Over
half of GPs (54.5%, 24/44) responded ‘Yes’ to this ques-
tion. Eighteen GPs (40.9%) did not consider ADHD to
be the primary diagnosis while two GPs did not know
(4.6%).
Group 2: adult patients who started pharmacological
treatment for ADHD in childhood or adolescence and
continued treatment into adulthood (n = 37)
i) Percentage of adult patients who receive/received
psychological interventions for ADHD
This information was reported as ‘Unknown’ or not re-
ported for five patients; therefore analyses were per-
formed on 32 patients (Table 3). Eighteen patients (56.3%)
had received/were receiving psychological interventions
for ADHD. Only four (12.5%) adult patients were
currently receiving psychological treatments, at the time
of questionnaire completion.
ii) Percentage of adult patients who receive/received
treatment for mental health comorbidities
GPs responded that this information was ‘Unknown’ for
three patients. Of the remaining 34 patients, eight (23.5%)
were stated to be receiving or had received treatment for
comorbid conditions, although the majority (76.5%, 26/
34) were not. Of these eight patients, three were currently
receiving treatment; two had received treatment within
the last five years and three patients received treatment
more than five years previously. The conditions for which
these eight patients were treated are presented in Table 4.
Table 3 Number of patients in Group 2 who receive/had
received psychological interventions for ADHD (n = 37)
Receiving psychological
intervention
Frequency % Definite answer¥
(n = 37) [95% CIs]
(n = 32)
Yes – currently 4 12.5
[3.5–29.0]
Yes – within the last year 2 6.3
[0.8–20.8]
Yes – within the last 5 years 9 28.1
[13.7–46.7]
Yes – more than 5 years ago 3 9.4
[2.0–25.0]
No 14 43.7
[26.4–62.3]
Unknown by GP/Information not
completed
4/1 N/A
¥ GPs provided a reason other than ‘Unknown’.
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listed by the GP.
iii) Extent to which shared care protocols exist between
primary and secondary care
For fewer than 20% of the patients (18.9%, 7/37) the
pharmacological treatment for ADHD was provided under
a shared care protocol with another healthcare professional.
iv) ADHD as the primary mental health diagnosis
GPs were asked if they considered ADHD to be the
primary mental health diagnosis for the patient. Over
three-quarters of GPs (78.4%, 29/37) responded ‘Yes’ to
this question. Six GPs (16.2%) did not consider ADHDTable 4 Patients in group 2 with comorbid conditions
and treatments prescribed for these
Comorbid conditions Frequency
(n = 8)
Treatment prescribed
(n = 4)
Obsessive Compulsive
Disorder
2 Antidepressants (1)¥/
Unknown by GP (1) *
Mood Disorder 1 Antidepressants (1) ¥
Personality Disorder 1 Methylphenidate (1) Δ
Learning Difficulties 1 No medication ¥
Aspergers 1 Unknown by GP *
Self-harm 1 Antipsychotics (1) Δ
Other – intracranial bleed,
facial palsy, hemiplegia
1 Unknown by GP *
¥- receiving treatment currently, Δ - within last 5 years, * - more than
5 years ago.to be the primary diagnosis while two GPs did not
know (5.4%).Group 3: patients who newly started pharmacological
treatment for ADHD in adulthood (n = 33)
i) Percentage of patients who received treatment for
other mental health conditions before the diagnosis
of ADHD was made
This information was reported as ‘Unknown’ by GPs
for two patients and so analyses were based on the
remaining 31 patients. Twenty adult patients (64.5%)
had been treated for other mental health conditions be-
fore they were diagnosed with ADHD (see below). The
remaining 11 patients (35.5%) had not received treat-
ment for other mental health conditions.
ii) Identified mental health conditions and their
treatment (pharmacological/psychological)
GPs were asked to list other mental health conditions
diagnosed and treated. Twelve of these 20 patients were
treated for a single condition, six patients for two
conditions, one for three conditions and one for four
conditions. The three most frequently reported conditions
for which patients were treated were; mood disorder (13),
personality disorder (five) and anxiety disorder (four). The
treated mental health conditions and the modality of
treatment are listed in Table 5. Of the 20 patients, 18
received pharmacological treatment (90%) of whom eight
also received psychological treatments. The other two
patients received psychological treatment only (10%).
iii) Percentage of patients who receive/received
treatment (pharmacological/psychological) for
mental health conditions in addition to ADHD
treatment
Seventeen adult patients (51.5%) were receiving or had
received treatment for other mental health conditions in
addition to ADHD treatment. Fourteen patients received
pharmacological treatment, eight of whom also received
psychological treatment. Three patients received psycho-
logical treatment only. Sixteen patients (48.5%) had not
received treatment for mental health conditions in
addition to ADHD treatment.
Of the 18 patients who were prescribed pharma-
cological treatment for other mental health conditions be-
fore the diagnosis of ADHD was made, 11 continued to
be prescribed pharmacological treatment for other mental
health conditions in addition to pharmacological treat-
ment for ADHD.
Table 5 Patients in group 3 with mental health conditions prior to and in addition to an ADHD diagnosis
Patients in group 3 with mental health conditions prior to being diagnosed with ADHD
(n = 20)
Patients in group 3 who were treated
for mental health conditions in
addition to ADHD treatment (n = 17)
Patient Mental health conditions Medications
prescribed*
Psychological
Interventions
Medications
prescribed*
Psychological
interventions
1 Mood
Disorder
Personality
Disorder
Substance
abuse
Depression Antidepressants,
Antipsychotics
Yes Antidepressants,
Sedatives, Anxiolytics as
required
Yes
2 Anxiety
Disorder
Personality
Disorder
Bulimia
Nervosa
Antidepressants Yes No No
3 Anxiety
Disorder
Personality
Disorder
No Yes No No
4 Mood
Disorder
Anxiety
Disorder
Antidepressants Yes No No
5 Mood
Disorder
Substance
Abuse
Antidepressants,
Sedatives
Unknown by
GP
Antidepressants Yes
6 Mood
Disorder
Personality
Disorder
Antidepressants Yes No Yes
7 Down’s
Syndrome
Behavioural
Problems
Sedatives No No No
8 Personality
Disorder
Substance
Abuse
Antipsychotics, Sedatives No Antipsychotics, Sedatives,
Other-trihexyphenidyl,
Pregabalin
Unknown by
GP
9 Anxiety
Disorder
Antidepressants, Mood
Stabilizers, Antipsychotics,
Sedatives
Yes Antidepressants,
Antipsychotics, Sedatives
Yes
10 Bipolar
Disorder
Antidepressants Yes Antipsychotics, Sedatives Yes
11 Mood
Disorder
Antidepressants,
Antipsychotics
No Antipsychotics Unknown by
GP
12 Mood
Disorder
Antidepressants,
Antipsychotics
No Antidepressants No
13 Mood
Disorder
Antidepressants No Antidepressants No
14 Mood
Disorder
Antidepressants No No No
15 Mood
Disorder
Antidepressants Yes No Yes
16 Mood
Disorder
Antidepressants Yes Antidepressants Yes
17 Mood
Disorder
Antidepressants No Antidepressants Yes
18 Mood
Disorder
Mood Stabilizers No No No
19 Mood
Disorder
No Yes Antipsychotics Yes
20 Learning
disabilities
Antidepressants,
Sedatives, Melatonin
No Antidepressants, Mood
Stabilizers, Antipsychotics
No
21¥ No No Antidepressants Yes
22¥ No No Antidepressants Unknown by
GP
23¥ No No No Yes
*It was not specified whether these were prescribed concurrently or sequentially.
¥ - patients not treated for other mental health conditions prior to ADHD diagnosis.
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primary and secondary care.For 39% of the patients (13/33) the pharmacological
treatment for ADHD was provided under a shared care
protocol with another healthcare professional.v) ADHD as the primary mental health diagnosisGPs were asked if they considered ADHD to be the
primary mental health diagnosis for the patient. Over
40% of GPs (42.4%, 14/33) responded ‘Yes’ to this ques-
tion. Ten GPs (30.3%) did not consider ADHD to be the
primary diagnosis while nine GPs did not know (27.3%).Discussion
Using data from a computerised UK primary care database,
of the 610 adult patients identified who had started ADHD
drug treatment in childhood, 358 (58.7%) of these patients
had stopped treatment before the age of 18 years, 252
(41.3%) continued ADHD drug treatment from childhood
into adulthood. Also 122 adult patients who had started
ADHD drug treatment in adulthood were identified. Data
from questionnaires sent to the GPs of a random sample of
50 patients from each of these three distinct patient groups,
were used to address issues with ADHD drug treatment
from childhood into adulthood (Groups 1 and 2) and in
adulthood (Group 3).
A high response rate was achieved in this study ranging
from 82% to 94% across the three study groups. There are
a number of factors which are likely to contribute to the
high response rate: the GPs who contribute data to the
THIN database, and who consent to providing additional
patient information, are a self-selected group and in
addition, those who completed and returned the question-
naire were compensated. A high response rate (>95%)
using the THIN database has been reported elsewhere
[18,22]. These response rates are higher than reported
in other GP studies; a review of published GP studies from
the early 1990s reported a mean response rate of 61%
[23]. These authors acknowledged that this figure was
likely to overestimate the true response rate as many stud-
ies with low response rates fail to get published.Reasons for stopping ADHD pharmacological treatment
before adulthood (Group 1)
In the current study, GPs were not aware of the reason for
stopping treatment in over one-third of patients. GPs,
who were aware of the reason(s), stated that it was the
patient’s decision to stop treatment in 56% of cases (14/25
who responded to this question). A qualitative study con-ducted by Wong et al. [7] in which patients were asked
directly for reasons for cessation of treatment in adoles-
cence reported in seven out of ten cases, the decision to
stop treatment was their own and was often influenced by
more than one factor. In addition, some patients who
stopped treatment did so because they felt they were able
to control themselves better than they could when they
were younger, whilst others had gravitated towards envi-
ronments and employment that did not place the same
demands on maintaining focus and concentration.
While it is recognized that symptoms of ADHD decline
over time in some patients, the prognosis of ADHD de-
pends on the definition of persistence used [4,24]. Studies
which have examined the persistence of the condition,
using the symptomatic definition of remission, reported
that the persistence of ADHD into adulthood was appro-
ximately 65% [4]. This current study was not designed to
estimate persistence of ADHD into adulthood, but ac-
cording to the patients’ GP, three of the 42 patients who
stopped treatment before adulthood reported experien-
cing ADHD symptoms after stopping pharmacological
treatment. Hence it may be prudent for GPs to review, on
a regular basis, older adolescents who stop medication for
ADHD in order to identify if symptoms and impairments
return and thus whether these patients require further as-
sessment and/or re-initiation of treatment.
Another reason cited for stopping treatment was the oc-
currence of side-effects, albeit in a low number of patients
(2/25). The three regulatory approved drugs in the UK
to treat ADHD have recognised and well established side-
effect profiles including (but not limited to) effects on
sleep, decreased appetite and the cardiovascular system.
Many of the common side-effects of these drugs are tran-
sient and subside with time or with reduced dosage, how-
ever serious/severe events may warrant discontinuation of
treatment. Although there have been some concerns of
the safety of ADHD treatment, it is generally accepted that
serious adverse reactions are uncommon [25,26]. In the
present study, details of the nature and severity of the
side-effects which resulted in discontinuation of the drug
were not reported by the GPs.
Other reasons contributing to patient cessation of
treatment which have been cited in the literature in-
clude the poor provision of treatment services for older
adolescents and young adults. Typically in the UK, pa-
tients with ADHD are under the care of child and ado-
lescent mental health services up to the age of 16 years
or school-leaving age with GPs responsible for prescrib-
ing ADHD medications [27]. However, ADHD services
within the adult mental health system in the UK are cur-
rently poorly developed [28] and clear arrangements for
transition are often lacking [29]. Wong et al. reported
this as a reason for stopping treatment in three out of
ten patients interviewed [7].
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There are a number of psychological treatments avail-
able for patients with ADHD, as an alternative to or
in combination with pharmacological treatment. The
NICE guidelines acknowledge that there is scant infor-
mation available on the use of this modality of treatment
[3]. The latest meta-analysis on nonpharmacological
interventions for ADHD indicate that better evidence for
efficacy from blinded assessments is required for behav-
ioral interventions, neurofeedback and cognitive trai-
ning before they can be supported as treatments for core
ADHD [30]. Psychological treatments for ADHD are cur-
rently likely to be limited to certain areas of the UK where
specialist services are available to provide such inter-
ventions and this is especially true for adult patients for
whom there are few specialist ADHD clinics [3].
In Group 1, GPs responded that 33% of patients re-
ceived psychological interventions for ADHD following
cessation of treatment. In Group 2, 56.3% of patients had
ever received psychological therapy in addition to pharma-
cological treatment for ADHD; 12.5% of patients were
currently receiving therapy.
Data from the current study showed great variability
between these two groups; however this may be in part
due to the small sample size of the individual groups.
This variability suggests that psychological treatment
may be considered either less favoured or less widely
available for the treatment of ADHD.
Treatment of other mental health conditions (Groups 1, 2
& 3)
The treatment of other psychological/psychiatric conditions
was investigated in the current study, with results varying
across the three patient groups.
The results demonstrate that in this sample of patients,
adult patients who initiated treatment for ADHD in adult-
hood were more frequently treated for other mental
health conditions prior to diagnosis of ADHD compared
to patients who started pharmacological treatment
for ADHD in childhood. The NICE report states that “In
adults, coexisting symptoms, syndromes and disorders are
frequently found to exist alongside the core ADHD syn-
drome, but their distinction from ADHD and the reasons
for high rates of coexistence are not well addressed in the
current literature” [3]. A recent review paper by Asherson
and colleagues highlight the many difficulties associated
with the presentation of ADHD in adults, with a particular
emphasis on high-functioning individuals, the challenges
of current diagnostic criteria, cultural influences on the
recognition of the disorder, and the burden of ADHD,
both socially and economically, on adults with the dis-
order [31]. An interview study, conducted by Matheson
and colleagues, examining adult ADHD patients’ ex-
periences of impairment, accessing services and treatmentmanagement, reported on the psychosocial burden from a
delayed diagnosis of ADHD in adulthood [32]. Patients
had sought help from services in childhood/adolescence
due to depression or anxiety, which resulted in years of
misdiagnoses and ineffective treatments; many patients
attributed the cause of comorbid disorders to underlying
ADHD. The effect of the delayed diagnosis was a chronic
sense of failure and missed potential in many areas of their
lives [32].
Shared-care arrangements (Groups 2 & 3)
NICE guidelines, published in 2008, recommend that “drug
treatment should only be initiated by an appropriately qua-
lified healthcare professional with expertise in ADHD and
should be based on a comprehensive assessment and diag-
nosis. Continued prescribing and monitoring of drug treat-
ment may be performed by general practitioners, under
shared care arrangements” [3]. However, although the ques-
tionnaire for the current study was administered in 2010,
the data obtained related to the study period 2003 to 2008,
therefore for the majority of patients, the NICE guidelines
were not in place when these patients were receiving treat-
ment. The data from the study revealed that at that time,
shared-care was not in place for all patients receiving treat-
ment for ADHD in adulthood (Groups 2 & 3). For
those patients in Group 2, who started treatment in child-
hood/adolescence, fewer than 20% were treated under
shared care protocols; however of those patients who
started in adulthood (Group 3) approximately 40% of pa-
tients had shared care. It was not possible to examine any
further differences e.g. geographical differences in the
provision of shared care across the UK; however it is recog-
nised that ADHD services within adult mental health care
are currently poorly developed in the UK [28]. NICE also
emphasized the benefit that such a service would bring in-
cluding ‘better care of young people with ADHD during
the transition between child and adolescent mental health
services (CAMHS) or paediatric services, and adult mental
health services’, ‘decreasing the number of people who
disengage from services’, and ‘improving the recognition,
diagnosis and treatment of ADHD in adults and reducing
the risk of misdiagnosis’ [33]. It would be important in fu-
ture studies to examine the provision of shared care and
the impact this has on the delivery of care to patients with
ADHD.
Strengths and limitations
This study utilised THIN data to access information on
a large cohort of patients with ADHD, across a wide age
range, who were treated in primary care. The services
provided by THIN also permitted the distribution and
retrieval of anonymised questionnaires from GPs which
enabled the analysis of information that is not routinely
coded in automated databases. The response rate
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90% in two of the groups. A limitation of the study was
the lower proportion of patients in Group 3 (adults who
started ADHD treatment in adulthood) who met the
study criteria; 73% in this group, compared with 94% in
Group 1 and 90% in Group 2. Patients in the latter two
groups were identified as having received their first pre-
scription for a study drug in childhood or adolescence
and followed forward into adulthood. Patients in Group
3 were also identified from the coded records on the
database. However, in responding to the questionnaire,
their GPs may have accessed information not coded on
the database which indicated an earlier (pre-adulthood)
prescription(s) for the treatment of ADHD. Historical
data on childhood disorders and their treatment may be
missing if patients move practices as adults; this may ac-
count for the difference in the number of valid cases be-
tween coded information and the response to the
questionnaires, and highlights the importance of verify-
ing electronic records with GP questionnaires.
For a number of questions asked, the answers were not
known by the GP. This was particularly the case when GPs
were asked for the reasons why patients in Group 1
stopped ADHD medication. It should be considered that
there may be systematic differences between those patients
for whom the reason was known such as engagement with
GP, etc. In addition to the small sample sizes in each group,
these missing data may be a source of bias to the study.
However, the fact that GPs don’t know the reason for cessa-
tion of treatment in many cases is important information
and reflects management practices for adult ADHD that
could be improved upon.
While this study included three cohorts of patients,
namely those who stopped ADHD treatment before adult-
hood, those who started treatment in childhood and
continued treatment into adulthood and those who started
treatment in adulthood, we were not able to investigate the
long-term outcomes of these groups due to the time period
of this study. It requires long-term monitoring to exa-
mine issues such as the benefits or risks of extended use of
pharmacological treatment on symptoms, impairments,
and quality of life for adult patients with ADHD.
Finally, although a large database was used to identify
patients, the small sample sizes in each group warrants
caution if data were extrapolated to the greater UK
population.Conclusions
A number of points for consideration were identified from
this study. The most frequent reason provided for stop-
ping treatment was patient choice not to continue medi-
cation, followed by improvement in symptoms, in the
cohort of adults who received pharmacological treatmentin childhood and stopped this treatment before reaching
adulthood. A small number of patients reported that they
experienced symptoms of ADHD of moderate severity
following cessation of pharmacological treatment; how-
ever only one patient received psychological therapy for
the treatment of these symptoms. The majority of patients
did not receive pharmacological treatments for comorbid
conditions after stopping ADHD medications.
Psychological treatments for ADHD were used by 12.5%
of patients who started treatment in childhood and
continued to receive pharmacological treatment in adult-
hood, at the time of questionnaire completion. Fewer than
one-quarter of these patients received pharmacological
treatment for comorbid mental health conditions, while
fewer than 20% of adults were receiving care under shared
care arrangements.
Almost two-thirds of patients were treated for another
mental health condition before the diagnosis of ADHD
was made in adulthood; the majority of whom received
pharmacological treatment. Approximately half of patients
received treatment for a mental health condition in
addition to receiving ADHD treatment. Fewer than half of
the patients were cared for under shared care arrange-
ments between primary care and specialist adult services.
This study has highlighted a number of key areas in
the treatment of ADHD patients, including the diagnosis
of ADHD in adults, the treatment of comorbid mental
health conditions and the delivery of care through
shared-care arrangements that warrant further research.
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